The CRISPR/Cas9 system, in conjunction with lipid-polymer hybrid nanoparticles (LPHNs-cRGD), was employed to achieve an efficient delivery of pCas9/MGMT plasmids into glioblastoma cells. The gene discussed is MGMT; the disease is glioblastoma.